0208080893 [email protected]
Providers / Bioss Primary Conjugated Antibodies. ALEXA FLUOR / SSX8 Antibody, ALEXA FLUOR 594

Description:

Size: 100ul

Catalog no.: bs-5975R-A594

Price: 380 EUR

Get for 380 EUR on Gentaur.com

/ningbo-assets-bio/graphics/prods/bigs/bigs0.jpg

Product details

Target Antigen

SSX8

Modification Site

None

Crossreactivity

Human

French translation

anticorps

Tested applications

IF(IHC-P)

Modification

Unmodified

Clonality

Polyclonal

Excitation emission

590nm/617nm

Concentration

1ug per 1ul

Conjugated with

ALEXA FLUOR® 594

Conjugated

Alexa conjugate 1

Recommended dilutions

IF(IHC-P)(1:50-200)

Clone

Polyclonal antibody

Purification

Purified by Protein A.

Conjugation

Alexa Fluor,ALEXA FLUOR® 594

Category

Conjugated Primary Antibodies

Also known as

Anti-SSX8 PAb ALEXA FLUOR 594

Host Organism

Rabbit (Oryctolagus cuniculus)

Specificity

This is a highly specific antibody against SSX8.

Long name

SSX8 Polyclonal Antibody, ALEXA FLUOR 594 Conjugated

Synonyms

Protein SSX8; SSX 8; SSX-8; Synovial sarcoma X breakpoint 8; SSX8_HUMAN.

Cross-reactive species details

Due to limited amount of testing and knowledge, not every possible cross-reactivity is known.

Source

This antibody was obtained by immunization of the host with KLH conjugated synthetic peptide derived from human SSX8

Storage conditions

Store this antibody in aqueous buffered solution containing 1% BSA, 50% glycerol and 0.09% sodium azide. Keep refrigerated at 2 to 8 degrees Celcius for up to one year.

Properties

For facs or microscopy Alexa 1 conjugate.If you buy Antibodies supplied by Bioss Primary Conjugated Antibodies. ALEXA FLUOR they should be stored frozen at - 24°C for long term storage and for short term at + 5°C.

Background of the antigen

SSX8 belongs to the family of highly homologous synovial sarcoma X (SSX) breakpoint proteins. These proteins may function as transcriptional repressors. They are also capable of eliciting spontaneously humoral and cellular immune responses in cancer patients, and are potentially useful targets in cancer vaccine-based immunotherapy. SSX1, SSX2 and SSX4 genes have been involved in the t(X;18) translocation characteristically found in all synovial sarcomas.